Fig 4.

EGFR V769M mutation is sensitive to erlotinib. (A and B) 293T cells were transiently transfected with plasmids that encode wild-type EGFR or EGFR mutants with the following changes: V769M, L858R, T790M. After 36 hours, cells were serum starved for 24 hours, treated with a different concentration of erlotinib for 3 hours, then harvested for immunoblot analyses. (A) Quantification of the protein expression was analyzed by using ImageJ, and (B) data were fitted using GraphPad Prism 6.0f (Appendix). Compared with sensitizing EGFR L858R and resistant T790M mutation, EGFR V769M mutation shows intermediate inhibition of phospho (p)-EGFR/total-EGFR by erlotinib. EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.